Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MARS2 | Q96GW9 | 4/20 | 0.43 |
| ▸ | ACHE | P22303 | 1/20 | 0.38 |
| ▸ | CREBBP | Q92793 | 2/20 | 0.37 |
| ▸ | CRHR1 | P34998 | 2/20 | 0.37 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.34 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.34 |
| ▸ | CLPP | Q16740 | 2/20 | 0.34 |
| ▸ | BRS3 | P32247 | 1/20 | 0.34 |
| ▸ | DRD4 | P21917 | 4/20 | 0.33 |
| ▸ | DRD2 | P14416 | 3/20 | 0.33 |
| ▸ | DRD3 | P35462 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30145209 | 1.00 | MARS2 (0.43) | MARS2ACHECREBBPCRHR1HDAC1 | |
| SCHEMBL30145155 | 0.87 | MARS2 (0.43) | MARS2ACHECRHR1HDAC1HDAC6 | |
| SCHEMBL20595933 | 0.87 | MARS2 (0.43) | MARS2ACHECRHR1HDAC1HDAC6 | |
| SCHEMBL20595993 | 0.83 | MARS2 (0.52) | MARS2ACHEHDAC1HDAC6CLPP | |
| SCHEMBL30145073 | 0.83 | MARS2 (0.52) | MARS2ACHEHDAC1HDAC6CLPP | |
| SCHEMBL20595863 | 0.82 | MARS2 (0.44) | MARS2ACHEDRD4DRD2DRD3 | |
| SCHEMBL30145203 | 0.82 | MARS2 (0.44) | MARS2ACHEDRD4DRD2DRD3 | |
| SCHEMBL20595906 | 0.81 | MARS2 (0.46) | MARS2ACHECLPPDRD4DRD2 | |
| SCHEMBL30145186 | 0.81 | MARS2 (0.46) | MARS2ACHECLPPDRD4DRD2 | |
| SCHEMBL20596106 | 0.77 | MARS2 (0.45) | MARS2ACHEDRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210155617-A1 | INHIBITORS OF TYPE l METHIONYL-TRNA SYNTHETASE AND METHODS OF USING THEM | UNIVERSITY OF WASHINGTON | 2021-05-27 | — | — | US | claimed |
| WO-2018237349-A1 | INHIBITORS OF TYPED 1 METHIONYL-TRNA SYNTHETASE AND METHODS OF USING THEM | UNIVERSITY OF WASHINGTON (US) | 2018-12-27 | — | — | WO | claimed |
| US-11584744-B2 | Inhibitors of type 1 methionyl-tRNA synthetase and methods of using them | UNIVERSITY OF WASHINGTON (US) | 2023-02-21 | — | — | US | disclosed |
| US-11584744-B2 | Inhibitors of type 1 methionyl-tRNA synthetase and methods of using them | UNIVERSITY OF WASHINGTON (US) | 2023-02-21 | — | — | US | disclosed |
| US-20210155617-A1 | INHIBITORS OF TYPE l METHIONYL-TRNA SYNTHETASE AND METHODS OF USING THEM | UNIVERSITY OF WASHINGTON | 2021-05-27 | — | — | US | disclosed |
| US-20210155617-A1 | INHIBITORS OF TYPE l METHIONYL-TRNA SYNTHETASE AND METHODS OF USING THEM | UNIVERSITY OF WASHINGTON | 2021-05-27 | — | — | US | disclosed |
| WO-2018237349-A1 | INHIBITORS OF TYPED 1 METHIONYL-TRNA SYNTHETASE AND METHODS OF USING THEM | UNIVERSITY OF WASHINGTON (US) | 2018-12-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11584744-B2 | Inhibitors of type 1 methionyl-tRNA synthetase and methods of using them | AARS1, EMG1, GARS1 | MARS2 12/4885ACHE 4482/4885CREBBP 1939/4885 |
| US-20210155617-A1 | INHIBITORS OF TYPE l METHIONYL-TRNA SYNTHETASE AND METHODS OF USING THEM | AARS1, GARS1, MTR | MARS2 5/4885ACHE 4249/4885CREBBP 1985/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.